Lost Money With NKTR? Contact Glancy Prongay Wolke & Rotter LLP
Nektar Therapeutics (NKTR)
Last nektar therapeutics earnings: 2/27 04:15 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.nektar.com/investor-relations
Company Research
Source: GlobeNewswire
LOS ANGELES, April 29, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP (“GPWR”), encourages Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR) investors to contact us about potentially pursuing claims to recover your loss under the federal securities laws. What Happened? A securities fraud class action has been filed against Nektar on behalf of investors who purchased stock between February 26, 2025 and December 15, 2025, inclusive (the “Class Period”). What’s The Next Step? Glancy Prongay Wolke & Rotter LLP is a leading national shareholder rights law firm, ready to assist you in potentially pursuing claims to recover your loss. If you wish to serve as lead plaintiff, you must move the Court no later than May 5, 2026. Please contact us to learn more about your rights and interests by clicking here, by email (shareholders@glancylaw.com), or by telephone at 310-201-9150 (Toll-Free: 888-773-9224). You may retain counsel of your choice. If you bought securiti
Show less
Read more
Impact Snapshot
Event Time:
NKTR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NKTR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NKTR alerts
High impacting Nektar Therapeutics news events
Weekly update
A roundup of the hottest topics
NKTR
News
- NEKTAR DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - NKTRACCESS Newswire
- NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Zalevsky Allegedly Overstated Enrollment Compliance: Levi & KorsinskyPR Newswire
- Class Action Litigation Filed by Pomerantz LLP Against Nektar Therapeutics, Inc. – NKTRACCESS Newswire
- NKTR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Nektar Therapeutics Shareholders Have Opportunity to Lead Class Action Lawsuit!ACCESS Newswire
- NKTR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Nektar Therapeutics Stockholders Have Opportunity to Lead Class Action Lawsuit!ACCESS Newswire
NKTR
Earnings
- 3/12/26 - Beat
NKTR
Sec Filings
- 4/24/26 - Form ARS
- 4/24/26 - Form DEFA14A
- 4/24/26 - Form DEF
- NKTR's page on the SEC website